Researchers have developed an adoptive cell immunology type treatment for melanoma and have achieved a complete remission using a patients own immune system to destroy the cancer.
These treatments are not compatible with most chemos, which damage the T cells needed o fight the cancer.
Timing could not be better for Solbec's Coramsine, now in Phase two trials against melanoma and renal. Coramsine does not do serious damage to the immune system and will fit with what could develop into a major shift in how cancer is treated.
The first cancer fighting vaccine is now approaching FDA approval. Dendreon is already completing their manufacturing facility for Provenge in NJ, the postrate vaccine treatment and following on with similar technology for breast, ovarian and others.In Phase 3 trials it has beaten the performance of the chemos with no serious side effects.
With good phase 2 results for Coramsine this could be exciting times for Solbec.
Good luck to solbec holders.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15614045&dopt=Abstract
SBP
solbec pharmaceuticals limited
